NEMAURA MEDICAL, INC. (OTCMKTS:NMRD) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02. Departure of Directors or Certain Officers; Election of Directors, Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.
On August 3, 2017, the Board of Directors of the Registrant appointed Mr. Thomas Moore as an independent director to serve on the Board of Directors, and on the Audit, Compensation and Nominating and Corporate Governance Committees.
Mr. Moore is currently working as a management consultant, having built up three decades of experience in the accountancy and consultancy fields at leading accountancy firms including Grant Thornton, KPMG and Price Waterhouse. He is a practicing Chartered Tax Adviser and earned his first class Bachelor of Arts in French and Russian from the University of Northumbria, UK.
Mr. Moore shall receive compensation in the amount of £1,250 (approximately USD1620) for each quarter per calendar year for his service on the Board, inclusive of his committee service. In addition, the Registrant shall issue Mr. Moore stock options to purchase up to 20,000 shares of the Company’s common stock on an annual basis. The initial issuance of such stock options shall be awarded on the date of the Registrant’s first public offering at an exercise price equal to the public offering price for such offering.
There are no family relationships between Mr. Moore and any of the officers of director of the Company. Mr. Moore has not engaged in any related party transactions.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
|
Exhibit No. |
Description |
|
10.1 |
Form of Director Agreement |
Nemaura Medical Inc. ExhibitEX-10.1 2 ex10x1.htm EXHIBIT 10.1 Exhibit 10.1 NEMAURA MEDICAL,…To view the full exhibit click here
About NEMAURA MEDICAL, INC. (OTCMKTS:NMRD)
Nemaura Medical, Inc. is a holding company. The Company owns a diagnostic medical device company specializing in discovering, developing and commercializing specialty medical devices. The Company’s focus is on the development of a continuous glucose monitoring (CGM) device, which consists of a disposable patch containing a sensor, and a non-disposable miniature electronic watch with a re-chargeable power source. CGM through a non-invasive patch can enable early detection of subtle changes in blood glucose levels. The Company, through its operating subsidiaries, performs medical device research and manufacturing of a CGM, named sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes, and may also be used to screen pre-diabetic patients. The sugarBEAT device extracts analytes, such as glucose, to the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm.
